Skip to Content
Søk Menu

BestPractice Nordic Covers the 2024 ASCO Gastrointestinal Cancers Symposium

BestPractice Nordic is excited to announce the coverage of the 2024 ASCO Gastrointestinal Cancers Symposium.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Anant Ramaswamy

Adding Docetaxel to FOLFOX/CAPOX in Gastric and Gastroesophageal Adenocarcinomas Does Not Improve Survival

/ Anant Ramaswamy
ASCOGI24Gastrointestinal kreft Play the Video 4:25
Thierry André

Nivolumab plus Ipilimumab – A Potential New Standard-of-Care Treatment Option for Patients with MSI-H/dMMR Advanced Metastatic Colorectal Cancer

/ Thierry André
ASCOGI24Kolorektal kreft Play the Video 3:48
Nicole Serapin

The Impact of COVID-19 on the Stage at Presentation for Colorectal Cancer Patients

/ Nicole Serapin
ASCOGI24Kolorektal kreft Play the Video 7:11
Kohei Shitara

CheckMate 649’s Four-Year Survival Data on Chemo + Nivolumab for Gastric & Esophageal Cancer

/ Kohei Shitara
ASCOGI24Gastrointestinal kreft Play the Video 02:55

ASCO GI 2024: Targeting HER2 in Gastroesophageal Adenocarcinoma

/ Sofie Pohl
ASCOGI24BrystkreftGastrointestinal kreft
Kohei Shitara

Management of Nausea and Vomiting Following First-Line Zolbetuximab + Chemotherapy

/ Kohei Shitara
ASCOGI24 Play the Video 03:33
Davi Said Gonçalves Celso

Meta Analysis of Three Trials: FAST, SPOTLIGHT & GLOW Exploring the New Target Claudin 18.2 in Gastric Cancer

/ Davi Said Gonçalves Celso
ASCOGI24Gastrointestinal kreft Play the Video 2:51
Yelena Janjigian

Global Insights from MATTERHORN: Unifying Gastric Cancer Treatment Standards with Durvalumab and FLOT

/ Yelena Janjigian
ASCOGI24Gastrointestinal kreft Play the Video 4:21
Van Morris

Circulating Tumor DNA – A Biomarker for Adjuvant Chemotherapy?

/ Van K. Morris
ASCOGI24Tarmkreft Play the Video 6:54
Back to top